NasdaqCM:DNTHBiotechs
Dianthus Therapeutics (DNTH) Stock After CAPTIVATE Results Looks Fairly Valued
Dianthus Therapeutics (DNTH) drew fresh attention after reporting positive midstage results from its CAPTIVATE Phase 3 trial in chronic inflammatory demyelinating polyneuropathy, highlighting a high confirmed responder rate along with a favorable safety profile.
See our latest analysis for Dianthus Therapeutics.
The CAPTIVATE data arrived after a strong run in Dianthus Therapeutics, with the share price at $78.88 and a year to date share price return of 98.79%. Short term momentum has cooled,...